Search Result

Results for "

potentiation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (1) Aminopeptidase (1) Amylin Receptor (1) Amyloid-β (2) Apoptosis (1) Autophagy (1) Bacterial (3) Beta-lactamase (1) CaMK (1) CFTR (2) Dopamine Receptor (2) Endogenous Metabolite (9) GABA Receptor (1) GlyT (4) Histone Acetyltransferase (1) iGluR (9) Isotope-Labeled Compounds (3) MAGL (1) mGluR (6) nAChR (2) Neprilysin (1) NF-κB (2) Opioid Receptor (1) Phosphodiesterase (PDE) (1) PROTACs (1)
By Research Areas:	Cancer (5) Endocrinology (1) Infection (3) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (32)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (1)

Aminopeptidase (1)

Amylin Receptor (1)

Amyloid-β (2)

Apoptosis (1)

Autophagy (1)

Bacterial (3)

Beta-lactamase (1)

CaMK (1)

CFTR (2)

Dopamine Receptor (2)

Endogenous Metabolite (9)

GABA Receptor (1)

GlyT (4)

Histone Acetyltransferase (1)

iGluR (9)

Isotope-Labeled Compounds (3)

MAGL (1)

mGluR (6)

nAChR (2)

Neprilysin (1)

NF-κB (2)

Opioid Receptor (1)

Phosphodiesterase (PDE) (1)

PROTACs (1)

By Research Areas:

Cancer (5)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (32)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101165

Cyclothiazide	iGluR	Neurological Disease
Cyclothiazide, a positive allosteric modulator of AMPA receptors, is used frequently to block the desensitization of both native and heterologously expressed AMPA receptors. Cyclothiazide is known to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current .

HY-N0403

2,3,4',5-Tetrahydroxystilbene 2-O-β-D-glucoside	Apoptosis	Inflammation/Immunology
2,3,4',5-Tetrahydroxystilbene 2-O-β-D-glucoside (TSG) is an active product that can be extracted from Polygonum multiflorum Thunb. TSG has anti-inflammatory, antioxidative, anti-atherosclerotic, anti-apoptotic, and free radical scavenging activities, TSG is also indicated to facilitate long-term potentiation and learning and memory in both normal and pathological conditions .

HY-13058B

(R)-ADX-47273	mGluR	Neurological Disease
(R)-ADX-47273 is a potent mGluR5 positive allosteric modulator, with an EC₅₀ of 168 nM for potentiation .

HY-103570

MCPG sodium	mGluR	Neurological Disease
MCPG is a carboxylic phenyl glycine. MCPG can block metabotropic glutamate receptor (mGluR)(HY-15129) and has antagonistic activity of mGluR subtype. MCPG can be used to study the induction and maintenance of long-term potentiation (LTP) .

HY-101165R

Cyclothiazide (Standard)	iGluR	Neurological Disease
Cyclothiazide (Standard) is the analytical standard of Cyclothiazide. This product is intended for research and analytical applications. Cyclothiazide, a positive allosteric modulator of AMPA receptors, is used frequently to block the desensitization of both native and heterologously expressed AMPA receptors. Cyclothiazide is known to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current .

HY-116143

MAGL-IN-12	MAGL	Metabolic Disease
SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC₅₀s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .

HY-103495

17-PA	GABA Receptor	Neurological Disease
17-PA is a selective antagonist of neurosteroid potentiation and direct gating of GABA ^A receptors .

HY-145440

Colistin adjuvant-2	Bacterial	Infection
Colistin adjuvant-2 is a colistin adjuvant, shows increased colistin potentiation activity against Gram-negative bacteria .

HY-160931

NMDA receptor modulator 8	iGluR	Neurological Disease
NMDA receptor modulator 8 (Compound 3-6) is a modulator for NMDA receptor, with 50%-100% potentiation of NMDA receptor at 10 μM .

HY-120386

LY382884	iGluR	Neurological Disease
LY382884 is a selective antagonist for GluR5 kainate receptor. LY382884 prevents the induction of NMDA receptor independent long-term potentiation (LTP) .

HY-116561

Adamantylmethamphetamine hydrochloride	Others	Neurological Disease
Adamantylmethamphetamine hydrochloride is a psychotic compound, possessing a central action. Adamantylmethamphetamine hydrochloride has effects on hexobarbital sleeping time, spontaneous motor activity, and the potentiation of metrazole and antifatigue activity .

HY-123782

(Rac)-UK-414495	Neprilysin	Metabolic Disease
(Rac)-UK-414495 (example 7) is a potent neutral endopeptidase (NEP) inhibitor. (Rac)-UK-414495 causes potentiation of cAMP in the sexual genitalia of the female .

HY-107683

LY-2087101	nAChR	Neurological Disease
LY-2087101 is an allosteric potentiator of α7 nAChRs. LY-2087101 causes potentiation of agonist-evoked α7 responses by binding within the nAChR transmembrane region .

HY-145439

Colistin adjuvant-1	Bacterial NF-κB	Infection
Colistin adjuvant-1 is a colistin adjuvant, shows increased colistin potentiation activity against Gram-negative bacteria. Colistin adjuvant-1 inhibits NF-κB with an IC₅₀ of 0.209 μM .

HY-I0096

Indole-2-carboxylic acid	Endogenous Metabolite iGluR	Neurological Disease
Indole-2-carboxylic acid is a strong inhibitor of lipid peroxidation. Indole-2-carboxylic acid (I2CA) specifically and competitively inhibits the potentiation by glycine of NMDA-gated current .

HY-111129

CP-66713	Adenosine Receptor	Neurological Disease
CP-66713 is a selective adenosine A2 receptor antagonist, with K_i of 22 nM. CP-66713 inhibits induction of long-term potentiation of evoked synaptic potentials. CP-66713 can be used in the study of neurological diseases .

HY-13058

ADX-47273 1 Publications Verification	mGluR	Neurological Disease
ADX-47273 is a potent, selective and brain-penetrant mGluR5 positive allosteric modulator (PAM), with an EC₅₀ of 0.17 μM for potentiation of glutamate (50 nM) response. ADX-47273 has antipsychotic and procognitive activities .

HY-100372

E4CPG (RS)-ECPG	mGluR	Neurological Disease
E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation .

HY-103409

ABT-724 trihydrochloride	Dopamine Receptor	Neurological Disease
ABT-724 trihydrochloride is a potent and highly selective dopamine D₄ receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D₄ receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D₄ (EC₅₀ of 14.3 nM) and the ferret D₄ receptor (EC₅₀ of 23.2 nM), and has no effect on dopamine D₁, D₂, D₃, or D₅ receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-14330

ABT-724	Dopamine Receptor	Neurological Disease
ABT-724 is a potent and highly selective dopamine D₄ receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D₄ receptor. ABT-724 is a potent partial agonist at the rat D₄ (EC₅₀ of 14.3 nM) and the ferret D₄ receptor (EC₅₀ of 23.2 nM). ABT-724 has no effect on dopamine D₁, D₂, D₃, or D₅ receptors. ABT-724 could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-Y0378

D-Leucine (R)-Leucine	Endogenous Metabolite	Neurological Disease
D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-P10235

Cyclic AC253	Amylin Receptor	Neurological Disease
Cyclic AC253 is an antagonist for amylin receptor, with IC₅₀ of 0.3 μM. Cyclic AC253 exhibits neuroprotective efficacy against Aβ toxicity and abrogates Aβ-induced impairment of hippocampal long-term potentiation. Cyclic AC253 penetrate blood-brain barrier (BBB) .

HY-101037

Sarcosine 1 Publications Verification N-Methylglycine; Sarcosin	Endogenous Metabolite GlyT	Cancer
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-N7119

Cimicifugoside	Others	Inflammation/Immunology
Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity . Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function .

HY-13017S

Ivacaftor-d9 VX-770-d₉	CFTR	Cancer
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research[1].

HY-13017S1

Ivacaftor-d19 VX-770-d₁₉	CFTR Autophagy	Endocrinology
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC₅₀ value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research .

HY-Y0378S

D-Leucine-d10 (R)-Leucine-d₁₀	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
D-Leucine-d₁₀ is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro[1].

HY-I0096S

Indole-2-carboxylic acid-13C	Isotope-Labeled Compounds Endogenous Metabolite iGluR	Neurological Disease
Indole-2-carboxylic acid- ¹³C is the ¹³C-labeled Indole-2-carboxylic acid. Indole-2-carboxylic acid is a strong inhibitor of lipid peroxidation. Indole-2-carboxylic acid (I2CA) specifically and competitively inhibits the potentiation by glycine of NMDA-gated current[1][2].

HY-101037S1

Sarcosine-d3 N-Methylglycine-d₃; Sarcosin-d₃	Isotope-Labeled Compounds Endogenous Metabolite GlyT	Cancer
Sarcosine-d₃ is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-109008

Nacubactam 2 Publications Verification OP0595 free acid	Beta-lactamase Bacterial	Infection
Nacubactam (OP0595 free acid) is a potent non-β-lactam-β-lactamase inhibitor with activity against class A and class C β-lactamases. Nacubactam (OP0595 free acid) acts as a penicillin binding protein (PBP) 2-active antibacterial, and gives β-lactamase-independent potentiation of β-lactams targeting other PBPs .

HY-148250

TP-050	iGluR	Neurological Disease
TP-050 is a potent, orally active and selective NMDAR agonist with an EC₅₀ value of 0.51 µM and 9.6 µM for GluN2A and GluN2D, respecticely. TP-050 can cross the blood-brain barrier (BBB). TP-050 induces hippocampal long-term (LPT) potentiation enhancemen and enhances neuronal signal transmission .

HY-Y0378R

D-Leucine (Standard)	Endogenous Metabolite	Neurological Disease
D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .

HY-101037R

Sarcosine (Standard)	Endogenous Metabolite GlyT	Cancer
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-101037S

Sarcosine-15N N-Methylglycine-¹⁵N; Sarcosin-¹⁵N	Endogenous Metabolite GlyT	Cancer
Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-120645

BMS-986122	Opioid Receptor	Neurological Disease
BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioid receptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ ³⁵S]GTPγS binding in mouse brain membranes .

HY-155687

PDE5-IN-10	Phosphodiesterase (PDE)	Neurological Disease
PDE5-IN-10 (compound 4b) is a potent PDE5 inhibitor with an IC₅₀ of 20 nM. PDE5-IN-10 improves in vitro microsomal stability (t_1/2 = 44.6 min) as well as excellent efficacy in restoring long-term potentiation. PDE5-IN-10 can be used for Alzheimer’s disease (AD) research .

HY-130553

β-Spaglumic acid 1 Publications Verification β-NAAG; β-N-Acetylaspartylglutamic acid	Aminopeptidase mGluR	Neurological Disease
β-Spaglumic acid (β-NAAG) is a competitive NAAG peptidase inhibitor (K_i=1 µM) that protects spinal cord neurons from excitotoxicity and hypoxic damage. β-Spaglumic acid is also a selective mGluR3 antagonist (mGluR3 receptor functions to regulate activity-dependent synaptic potentiation in the hippocampus). β-Spaglumic acid can be used in neuroprotection-related studies .

HY-N2922

β-Amyrin	Amyloid-β NF-κB	Neurological Disease Inflammation/Immunology
β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound .

HY-N2922R

β-Amyrin (Standard)	Amyloid-β	Neurological Disease
β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound .

HY-19411

SSR180711 hydrochloride	nAChR	Neurological Disease
SSR180711 hydrochloride is an orally active, selective and reversible α7 acetylcholine nicotinic receptor (n-AChRs) partial agonist. SSR180711 hydrochloride can act on rat α7 n-AChR (K_i=22 nM; IC₅₀=30 nM) and human α7 n-AChR (K_i=14 nM; IC₅₀=18 nM). SSR180711 hydrochloride increases glutamatergic neurotransmission, ACh release and long-term potentiation (LTP) in the hippocampus .

HY-121299

m-Chlorophenylbiguanide mCPBG	5-HT Receptor	Neurological Disease
m-Chlorophenylbiguanide (mCPBG) is a potent high-affinity agonist of the 5-HT3 receptor, exhibiting an inhibitory effect on long-term potentiation (LTP) in the mossy fiber-CA3 system. mCPBG attenuates the magnitude of LTP at concentrations of 0.3-1 microM, demonstrating its role in modulating synaptic plasticity. Additionally, the impact of mCPBG on LTP is reversible by the GABAA receptor antagonist bicuculline, indicating a connection between its action and GABAergic neurotransmission.

HY-100617A

(RS)-4CPG (RS)-4-Carboxyphenylglycine	mGluR	Others
(RS)-4CPG ((RS)-4-Carboxyphenylglycine) is a type I metabotropic glutamate receptor antagonist with activity in blocking LTP induction. In mice lacking IP3R1, (RS)-4CPG (500μM) nearly blocked long-term potentiation (LTP) induced by type I metabotropic glutamate receptor activation, with LTP of 117.6±1.7% (n = 8) in IP3R1(-/-) mice and 116.9±1.8% (n = 5) in IP3R1(+/+) mice.

HY-107601

UBP316 ACET	iGluR	Neurological Disease
UBP316 (ACET) is a highly potent and selective kainate receptor GluK1 (GluR5) antagonist, with a K_b value of 1.4 nM. UBP316 is effective at blocking the depression of both field excitatory postsynaptic potentials (fEPSPs) and monosynaptically-evoked GABAergic transmission induced by ATPA, a GluK1 selective agonist .

HY-156104

CaMKIIα-PHOTAC	PROTACs CaMK	Neurological Disease
CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .

HY-16728A

Rapastinel acetate GLYX-13 acetate	iGluR	Neurological Disease
Rapastinel acetate (GLYX-13 acetate) is an N-methyl-D-aspartate (NMDA) receptor modulator with long-acting antidepressant activity. Rapastinel acetate exerts its antidepressant effects by enhancing long-term potentiation (LTP) of synaptic transmission. Rapastinel acetate transiently enhances NMDAR-mediated currents in pyramidal neurons in the hippocampus and medial prefrontal cortex by binding to unique sites on the NMDAR complex. Rapastinel acetate significantly enhanced NMDAR-mediated currents at a concentration of 1 μmol/l and significantly reduced the currents at a concentration of 10 μmol/l. The mechanism of action of Rapastinel acetate is related to the reduction of affinity to intracellular calcium inactivation sites, which provides a theoretical basis for enhancing conductance mediated by NMDAR .

HY-116673

TTK21	Histone Acetyltransferase	Neurological Disease
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .

Cat. No.	Product Name	Target	Research Area